Dyne Therapeutics
DYN · NASDAQ
$16.27+$1.04 (+6.83%)TodayMarket closed ·
Prev close $15.23
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 7.1% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- -$0.89
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.7582 | -$1.08 | −42.4% |
| Q1 FY26 | -$0.7808 | -$0.73 | +6.5% |
| Q4 FY25 | -$0.7777 | -$0.76 | +2.3% |
| Q3 FY25 | -$0.8457 | -$0.76 | +10.1% |
| Q2 FY25 | -$0.9642 | -$0.97 | −0.6% |
| Q1 FY25 | -$0.888 | -$1.05 | −18.2% |
| Q4 FY24 | -$0.9705 | -$0.88 | +9.3% |
| Q3 FY24 | -$0.7191 | -$0.96 | −33.5% |
Earnings calls
- Morgan Stanley 24th Annual Global Healthcare Conference
- TD Cowen 46th Annual Health Care Conference
- 44th Annual J.P. Morgan Healthcare Conference
- Special Call - Dyne Therapeutics, Inc.
- Morgan Stanley 23rd Annual Global Healthcare Conference
- Special Call - Dyne Therapeutics, Inc.
- 43rd Annual J.P. Morgan Healthcare Conference 2025
- Special Call - Dyne Therapeutics, Inc.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.